{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:46Z","timestamp":1790991646994,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00830-x","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:26:14Z","timestamp":1758471974000},"page":"2387-2410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neurofilament Light Chain Levels as Diagnostic and Prognostic Biomarkers in Guillain\u2013Barr\u00e9 Syndrome: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Giovanni","family":"Siconolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ausilia","family":"Sciarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Guglielmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Primiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-505X","authenticated-orcid":false,"given":"Marco","family":"Luigetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"issue":"10280","key":"830_CR1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S. Guillain\u2013Barr\u00e9 syndrome. Lancet. 2021;397(10280):1214\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(21)00517-1.","journal-title":"Lancet"},{"issue":"4","key":"830_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/wnl.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs BC, Rothbarth PH, van der Mech\u00e9 FG, et al. The spectrum of antecedent infections in Guillain\u2013Barr\u00e9 syndrome: a case-control study. Neurology. 1998;51(4):1110\u20135. https:\/\/doi.org\/10.1212\/wnl.51.4.1110.","journal-title":"Neurology"},{"issue":"7","key":"830_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","volume":"74","author":"Z Islam","year":"2010","unstructured":"Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain\u2013Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology. 2010;74(7):581\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e3181cff735.","journal-title":"Neurology"},{"issue":"11","key":"830_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671\u201383. https:\/\/doi.org\/10.1038\/s41582-019-0250-9.","journal-title":"Nat Rev Neurol"},{"issue":"Pt 3","key":"830_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/brain\/105.3.481","volume":"105","author":"AN Al-Din","year":"1982","unstructured":"Al-Din AN, Anderson M, Bickerstaff ER, Harvey I. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain. 1982;105(Pt 3):481\u201395. https:\/\/doi.org\/10.1093\/brain\/105.3.481.","journal-title":"Brain"},{"issue":"1","key":"830_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","volume":"86","author":"YA Rajabally","year":"2015","unstructured":"Rajabally YA, Durand MC, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain\u2013Barr\u00e9 syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015;86(1):115\u20139. https:\/\/doi.org\/10.1136\/jnnp-2014-307815.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"830_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ana.21976","volume":"67","author":"C Walgaard","year":"2010","unstructured":"Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome. Ann Neurol. 2010;67(6):781\u20137. https:\/\/doi.org\/10.1002\/ana.21976.","journal-title":"Ann Neurol"},{"issue":"4","key":"830_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jns.12286","volume":"23","author":"C Walgaard","year":"2018","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, et al. Second IVIg course in Guillain\u2013Barr\u00e9 syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst. 2018;23(4):210\u20135. https:\/\/doi.org\/10.1111\/jns.12286.","journal-title":"J Peripher Nerv Syst"},{"key":"830_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/564098","volume":"2015","author":"Y Wang","year":"2015","unstructured":"Wang Y, Sun S, Zhu J, Cui L, Zhang HL. Biomarkers of Guillain\u2013Barr\u00e9 syndrome: some recent progress, more still to be explored. Mediators Inflamm. 2015;2015:564098. https:\/\/doi.org\/10.1155\/2015\/564098.","journal-title":"Mediators Inflamm"},{"issue":"8","key":"830_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870\u201381. https:\/\/doi.org\/10.1136\/jnnp-2018-320106.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"830_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389. https:\/\/doi.org\/10.1038\/s41582-018-0058-z.","journal-title":"Nat Rev Neurol"},{"key":"830_CR12","doi-asserted-by":"publisher","unstructured":"Fundaun J, Kolski M, Molina-\u00c1lvarez M, Baskozos G, Schmid AB. Types and concentrations of blood-based biomarkers in adults with peripheral neuropathies: a systematic review and meta-analysis. JAMA Netw Open. 2022. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48593.","DOI":"10.1001\/jamanetworkopen.2022.48593"},{"issue":"12","key":"830_CR13","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","volume":"30","author":"PA van Doorn","year":"2023","unstructured":"van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain\u2013Barr\u00e9 syndrome. Eur J Neurol. 2023;30(12):3646\u201374. https:\/\/doi.org\/10.1111\/ene.16073.","journal-title":"Eur J Neurol"},{"issue":"6","key":"830_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/sim.8013","volume":"38","author":"S McGrath","year":"2019","unstructured":"McGrath S, Zhao X, Qin ZZ, Steele R, Benedetti A. One-sample aggregate data meta-analysis of medians. Stat Med. 2019;38(6):969\u201384. https:\/\/doi.org\/10.1002\/sim.8013.","journal-title":"Stat Med"},{"key":"830_CR15","unstructured":"McGrath S, Zhao X, Steele R, Benedetti A. estmeansd: estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Published online Dec 14, 2023. https:\/\/cran.r-project.org\/web\/packages\/estmeansd\/index.html. Accessed Aug 21, 2025."},{"key":"830_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"830_CR17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat Methods Med Res"},{"key":"830_CR18","unstructured":"metacor.pdf. https:\/\/web.archive.org\/web\/20210716153541id_\/https:\/\/repo.bppt.go.id\/cran\/web\/packages\/metacor\/metacor.pdf. Accessed 16 Aug 2025."},{"issue":"5","key":"830_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/acn3.51355","volume":"8","author":"A Gauthier","year":"2021","unstructured":"Gauthier A, Viel S, Perret M, et al. Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis. Ann Clin Transl Neurol. 2021;8(5):1141\u201350. https:\/\/doi.org\/10.1002\/acn3.51355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"830_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54(10):1655\u201361. https:\/\/doi.org\/10.1515\/cclm-2015-1195.","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"830_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70215","volume":"32","author":"G Primiano","year":"2025","unstructured":"Primiano G, Luigetti M, Righi D, et al. Comparative analysis of SiMoA and Ella immunoassay platforms for measuring serum neurofilament light chain levels in ATTRv with polyneuropathy and presymptomatic carriers. Eur J Neurol. 2025;32(6):e70215. https:\/\/doi.org\/10.1111\/ene.70215.","journal-title":"Eur J Neurol"},{"issue":"1","key":"830_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","volume":"17","author":"P Altmann","year":"2020","unstructured":"Altmann P, De Simoni D, Kaider A, et al. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain\u2013Barr\u00e9 syndrome. J Neuroinflammation. 2020;17(1):86. https:\/\/doi.org\/10.1186\/s12974-020-01737-0.","journal-title":"J Neuroinflammation"},{"key":"830_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323899","author":"L Mart\u00edn-Aguilar","year":"2020","unstructured":"Mart\u00edn-Aguilar L, Camps-Renom P, Lleix\u00e0 C, et al. Serum neurofilament light chain predicts long-term prognosis in Guillain\u2013Barr\u00e9 syndrome patients. J Neurol Neurosurg Psychiatry. 2020. https:\/\/doi.org\/10.1136\/jnnp-2020-323899.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"830_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16539","volume":"32","author":"AM Afzali","year":"2025","unstructured":"Afzali AM, Vosko M, Reinhardt N, et al. Serum neurofilament light chain predicts disease severity in axonal variants of acute immune neuropathies: a retrospective monocentric cohort study. Eur J Neurol. 2025;32(1):e16539. https:\/\/doi.org\/10.1111\/ene.16539.","journal-title":"Eur J Neurol"},{"issue":"9","key":"830_CR25","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/ene.15428","volume":"29","author":"I Kmezic","year":"2022","unstructured":"Kmezic I, Samuelsson K, Finn A, et al. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. Eur J Neurol. 2022;29(9):2810\u201322. https:\/\/doi.org\/10.1111\/ene.15428.","journal-title":"Eur J Neurol"},{"key":"830_CR26","doi-asserted-by":"publisher","unstructured":"Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018. https:\/\/doi.org\/10.1111\/jns.12279.","DOI":"10.1111\/jns.12279"},{"issue":"11","key":"830_CR27","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/acn3.51207","volume":"7","author":"P K\u00f6rtvelyessy","year":"2020","unstructured":"K\u00f6rtvelyessy P, Kuhle J, D\u00fczel E, et al. Ratio and index of neurofilament light chain indicate its origin in Guillain\u2013Barr\u00e9 syndrome. Ann Clin Transl Neurol. 2020;7(11):2213\u201320. https:\/\/doi.org\/10.1002\/acn3.51207.","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"830_CR28","doi-asserted-by":"publisher","first-page":"7282","DOI":"10.1007\/s00415-024-12679-5","volume":"271","author":"B Hafsteinsd\u00f3ttir","year":"2024","unstructured":"Hafsteinsd\u00f3ttir B, Farman H, Lagerstr\u00f6m N, et al. Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain\u2013Barr\u00e9 syndrome. J Neurol. 2024;271(11):7282\u201393. https:\/\/doi.org\/10.1007\/s00415-024-12679-5.","journal-title":"J Neurol"},{"key":"830_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105072","volume":"102","author":"SJ van Tilburg","year":"2024","unstructured":"van Tilburg SJ, Teunissen CE, Maas CCHM, et al. Dynamics and prognostic value of serum neurofilament light chain in Guillain\u2013Barr\u00e9 syndrome. EBioMedicine. 2024;102:105072. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105072.","journal-title":"EBioMedicine"},{"issue":"2","key":"830_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ane.12927","volume":"138","author":"M Axelsson","year":"2018","unstructured":"Axelsson M, Sj\u00f6gren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain\u2013Barr\u00e9 syndrome: a pilot study. Acta Neurol Scand. 2018;138(2):143\u201350. https:\/\/doi.org\/10.1111\/ane.12927.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"830_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jns.12608","volume":"29","author":"LS Kodal","year":"2024","unstructured":"Kodal LS, Witt AM, Pedersen BS, Aagaard MM, Dysgaard T. Prognostic value of neurofilament light in blood in patients with polyneuropathy: a systematic review. J Peripher Nerv Syst. 2024;29(1):17\u201327. https:\/\/doi.org\/10.1111\/jns.12608.","journal-title":"J Peripher Nerv Syst"},{"issue":"31","key":"830_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2169","volume":"7","author":"M Karlsson","year":"2021","unstructured":"Karlsson M, Zhang C, M\u00e9ar L, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021;7(31):eabh2169. https:\/\/doi.org\/10.1126\/sciadv.abh2169.","journal-title":"Sci Adv"},{"issue":"1","key":"830_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neumar.2024.100003","volume":"1","author":"J Berciano","year":"2024","unstructured":"Berciano J. Pathophysiology and markers of very early classic Guillain\u2013Barr\u00e9 syndrome. NeuroMarkers. 2024;1(1):100003. https:\/\/doi.org\/10.1016\/j.neumar.2024.100003.","journal-title":"NeuroMarkers"},{"issue":"1","key":"830_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ana.410390103","volume":"39","author":"HC Powell","year":"1996","unstructured":"Powell HC, Myers RR. The axon in Guillain\u2013Barr\u00e9 syndrome: immune target or innocent bystander? Ann Neurol. 1996;39(1):4\u20135. https:\/\/doi.org\/10.1002\/ana.410390103.","journal-title":"Ann Neurol"},{"issue":"1","key":"830_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jns.12532","volume":"28","author":"ME Cunningham","year":"2023","unstructured":"Cunningham ME, McGonigal R, Barrie JA, Campbell CI, Yao D, Willison HJ. Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain\u2013Barr\u00e9 syndrome. J Peripher Nerv Syst. 2023;28(1):17\u201331. https:\/\/doi.org\/10.1111\/jns.12532.","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"830_CR36","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","volume":"94","author":"B Delcoigne","year":"2020","unstructured":"Delcoigne B, Manouchehrinia A, Barro C, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94(11):e1201\u201312. https:\/\/doi.org\/10.1212\/WNL.0000000000009097.","journal-title":"Neurology"},{"issue":"10","key":"830_CR37","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315. https:\/\/doi.org\/10.1212\/WNL.0000000000007032.","journal-title":"Neurology"},{"key":"830_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852563","volume":"13","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, Arnold DL, Alvarez E, et al. Prognostic value of serum neurofilament light chain for disease activity and worsening in patients with relapsing multiple sclerosis: results from the phase\u00a03 ASCLEPIOS I and II trials. Front Immunol. 2022;13:852563. https:\/\/doi.org\/10.3389\/fimmu.2022.852563.","journal-title":"Front Immunol"},{"issue":"6","key":"830_CR39","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"\u00c5 Sandelius","year":"2018","unstructured":"Sandelius \u00c5, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518\u201324. https:\/\/doi.org\/10.1212\/WNL.0000000000004932.","journal-title":"Neurology"},{"key":"830_CR40","doi-asserted-by":"publisher","unstructured":"Luigetti M, Primiano G, Basile V, et al. Serum neurofilament and free light chain levels in patients undergoing treatment for chronic inflammatory demyelinating polyneuropathy. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25021254.","DOI":"10.3390\/ijms25021254"},{"issue":"4","key":"830_CR41","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s10072-021-05850-7","volume":"43","author":"M Luigetti","year":"2022","unstructured":"Luigetti M, Di Paolantonio A, Guglielmino V, et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience. Neurol Sci. 2022;43(4):2845\u20138. https:\/\/doi.org\/10.1007\/s10072-021-05850-7.","journal-title":"Neurol Sci"},{"issue":"1","key":"830_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16070","volume":"31","author":"A Romano","year":"2024","unstructured":"Romano A, Primiano G, Antonini G, et al. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis? Eur J Neurol. 2024;31(1):e16070. https:\/\/doi.org\/10.1111\/ene.16070.","journal-title":"Eur J Neurol"},{"issue":"1","key":"830_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s40478-024-01883-z","volume":"12","author":"JD Arena","year":"2024","unstructured":"Arena JD, Smith DH, Diaz Arrastia R, et al. The neuropathological basis of elevated serum neurofilament light following experimental concussion. Acta Neuropathol Commun. 2024;12(1):189. https:\/\/doi.org\/10.1186\/s40478-024-01883-z.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"830_CR44","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000009983","volume":"95","author":"P Shahim","year":"2020","unstructured":"Shahim P, Politis A, van der Merwe A, et al. Neurofilament light as a biomarker in traumatic brain injury. Neurology. 2020;95(6):e610\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000009983.","journal-title":"Neurology"},{"issue":"4","key":"830_CR45","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.clinph.2014.06.051","volume":"126","author":"E Gallardo","year":"2015","unstructured":"Gallardo E, Sedano MJ, Orizaola P, et al. Spinal nerve involvement in early Guillain\u2013Barr\u00e9 syndrome: a clinico-electrophysiological, ultrasonographic and pathological study. Clin Neurophysiol. 2015;126(4):810\u20139. https:\/\/doi.org\/10.1016\/j.clinph.2014.06.051.","journal-title":"Clin Neurophysiol"},{"key":"830_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.4.552","author":"J Berciano","year":"2000","unstructured":"Berciano J, Garc\u00eda A, Figols J, Mu\u00f1oz R, Berciano MT, Lafarga M. Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy. Neurology. 2000. https:\/\/doi.org\/10.1212\/wnl.55.4.552.","journal-title":"Neurology"},{"issue":"5","key":"830_CR47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF00296547","volume":"82","author":"HC Powell","year":"1991","unstructured":"Powell HC, Myers RR, Mizisin AP, Olee T, Brostoff SW. Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T\u00a0cell lines. Acta Neuropathol. 1991;82(5):364\u201377. https:\/\/doi.org\/10.1007\/BF00296547.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"830_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200405","volume":"12","author":"F Shimizu","year":"2025","unstructured":"Shimizu F, Koga M, Mizukami Y, et al. Small nuclear ribonucleoprotein autoantibody associated with blood-nerve barrier breakdown in Guillain\u2013Barr\u00e9 syndrome. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200405. https:\/\/doi.org\/10.1212\/NXI.0000000000200405.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"830_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410390105","volume":"39","author":"JW Griffin","year":"1996","unstructured":"Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain\u2013Barr\u00e9 syndrome. Ann Neurol. 1996;39(1):17\u201328. https:\/\/doi.org\/10.1002\/ana.410390105.","journal-title":"Ann Neurol"},{"key":"830_CR50","doi-asserted-by":"publisher","unstructured":"Kalm M, Bostr\u00f6m M, Sandelius \u00c5, et al. Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Res. 2017. https:\/\/doi.org\/10.1016\/j.brainres.2017.05.011.","DOI":"10.1016\/j.brainres.2017.05.011"},{"key":"830_CR51","doi-asserted-by":"publisher","DOI":"10.1159\/000513877","author":"A Toft","year":"2020","unstructured":"Toft A, Roos P, J\u00e4\u00e4skel\u00e4inen O, et al. Serum neurofilament light in patients with frontotemporal dementia caused by CHMP2B Mutation. Dement Geriatr Cogn Disord. 2020. https:\/\/doi.org\/10.1159\/000513877.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"830_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/0004-282X-anp-2020-0094","volume":"79","author":"H Reiber","year":"2021","unstructured":"Reiber H. Blood-cerebrospinal fluid (CSF) barrier dysfunction means reduced CSF flow not barrier leakage - conclusions from CSF protein data. Arq Neuro-Psiquiatr. 2021;79:56\u201367. https:\/\/doi.org\/10.1590\/0004-282X-anp-2020-0094.","journal-title":"Arq Neuro-Psiquiatr"},{"key":"830_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.746186","author":"Y Tu","year":"2021","unstructured":"Tu Y, Gong X, Zhang Y, Peng J, Zhuo W, Yu X. The correlation among the immunoglobulin\u00a0G synthesis RATE, IgG index and albumin quotient in Guillain\u2013Barr\u00e9 Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy: a retrospective case-control study. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.746186.","journal-title":"Front Neurol"},{"issue":"3","key":"830_CR54","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/ene.14600","volume":"28","author":"H Hegen","year":"2021","unstructured":"Hegen H, Ladst\u00e4tter F, Bsteh G, et al. Cerebrospinal fluid protein in Guillain\u2013Barr\u00e9 syndrome: need for age-dependent interpretation. Eur J Neurol. 2021;28(3):965\u201373. https:\/\/doi.org\/10.1111\/ene.14600.","journal-title":"Eur J Neurol"},{"issue":"9","key":"830_CR55","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1007\/s00415-021-10479-9","volume":"268","author":"J Rath","year":"2021","unstructured":"Rath J, Zulehner G, Schober B, et al. Cerebrospinal fluid analysis in Guillain\u2013Barr\u00e9 syndrome: value of albumin quotients. J Neurol. 2021;268(9):3294\u2013300. https:\/\/doi.org\/10.1007\/s00415-021-10479-9.","journal-title":"J Neurol"},{"key":"830_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf234","author":"R Bellanti","year":"2025","unstructured":"Bellanti R, Keh RYS, Keddie S, et al. Plasma periaxin is a biomarker of peripheral nerve demyelination. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf234.","journal-title":"Brain"},{"key":"830_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.imlet.2017.03.011","volume":"185","author":"A Niezgoda","year":"2017","unstructured":"Niezgoda A, Michalak S, Losy J, Kalinowska-\u0141yszczarz A, Kozubski W. sNCAM as a specific marker of peripheral demyelination. Immunol Lett. 2017;185:93\u20137. https:\/\/doi.org\/10.1016\/j.imlet.2017.03.011.","journal-title":"Immunol Lett"},{"issue":"1","key":"830_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70009","volume":"30","author":"QD Mohammad","year":"2025","unstructured":"Mohammad QD, Islam Z, Papri N, et al. Results from a phase\u00a01 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ANX005, a C1q inhibitor, in patients with Guillain\u2013Barr\u00e9 syndrome. J Peripher Nerv Syst. 2025;30(1):e70009. https:\/\/doi.org\/10.1111\/jns.70009.","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"830_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/jns.12646","volume":"29","author":"S Kuwabara","year":"2024","unstructured":"Kuwabara S, Kusunoki S, Kuwahara M, et al. Efficacy and safety of eculizumab in Guillain\u2013Barr\u00e9 syndrome: a phase\u00a03, multicenter, double-blind, randomized, placebo-controlled clinical trial. J Peripher Nerv Syst. 2024;29(3):339\u201349. https:\/\/doi.org\/10.1111\/jns.12646.","journal-title":"J Peripher Nerv Syst"},{"key":"830_CR60","doi-asserted-by":"publisher","unstructured":"Predicting outcome in Guillain\u2013Barr\u00e9 syndrome. Neurology. 2024;103(9):e209968. https:\/\/doi.org\/10.1212\/WNL.0000000000209968.","DOI":"10.1212\/WNL.0000000000209968"},{"issue":"16","key":"830_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612751","volume":"24","author":"X Capo","year":"2023","unstructured":"Capo X, Galmes-Panades AM, Navas-Enamorado C, et al. Circulating neurofilament light chain levels increase with age and are associated with worse physical function and body composition in men but not in women. Int J Mol Sci. 2023;24(16):12751. https:\/\/doi.org\/10.3390\/ijms241612751.","journal-title":"Int J Mol Sci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00830-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:19Z","timestamp":1763376319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00830-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,21]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00830-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,21]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marco Luigetti is an Editorial Board member of\n                      Neurology and Therapy\n                      . Marco Luigetti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Giovanni Siconolfi, Francesca Vitali, Maria Ausilia Sciarrone, Guido Primiano and Valeria Guglielmino have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients in our cohort for participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}